Dosing of sublingual immunotherapy for allergic rhinitis

Evidence-based review with recommendations

Bryan D. Leatherman, Ayesha Khalid, Stella Lee, Kevin Mcmains, Jacques Peltier, Michael P. Platt, Robert J. Stachler, Elina Toskala, Guy Tropper, Giri Venkatraman, Sandra Y Lin

Research output: Contribution to journalArticle

Abstract

Background: Since the mid 1980s, the clinical use of sublingual immunotherapy (SLIT) has dramatically increased. However, 1 of the primary barriers to providing SLIT is lack of a published dosing recommendations. The purpose of this work is to provide a range of effective SLIT dosing based upon a rigorous review of the existing evidence base. An appendix with SLIT dosing recommendations is also included. Methods: A comprehensive search of the past 25 years of the medical literature using PubMed was performed for specific antigens. Inclusion criteria for articles included: randomized, placebo-controlled studies of SLIT, studies with clinical allergic rhinitis outcomes, and dosing units available to determine the micrograms per month of major allergen administered. The extracted data was used to compile a range of effective SLIT dosing for individual antigens. Results: Seventy-five articles met the inclusion criteria, providing a range of effective dosing for some allergens. There was commonly a wide range in doses for particular antigens between the individual studies. For some antigens, there was significant overlap in dosage amount between studies showing efficacy and lack of efficacy. Clinical trials meeting inclusion criteria are not available for many allergens. Conclusion: This study provided a comprehensive review of the published sublingual dosing ranges for specific antigens. The review provided a range of effective sublingual doses for some allergens, whereas for other allergens there was insufficient published data to determine specific doses. Recommendations for SLIT dosing were produced based on the data revealed in the review and expert opinion.

Original languageEnglish (US)
Pages (from-to)773-783
Number of pages11
JournalInternational Forum of Allergy and Rhinology
Volume5
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Sublingual Immunotherapy
Allergens
Antigens
Expert Testimony
Allergic Rhinitis
PubMed
Placebos
Clinical Trials

Keywords

  • Aeroallergens
  • Allergic conjunctivitis
  • Allergy injections
  • Asthma
  • Evidence-based medicine
  • Subcutaneous immunotherapy
  • Sublingual immunotherapy
  • Type I allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Dosing of sublingual immunotherapy for allergic rhinitis : Evidence-based review with recommendations. / Leatherman, Bryan D.; Khalid, Ayesha; Lee, Stella; Mcmains, Kevin; Peltier, Jacques; Platt, Michael P.; Stachler, Robert J.; Toskala, Elina; Tropper, Guy; Venkatraman, Giri; Lin, Sandra Y.

In: International Forum of Allergy and Rhinology, Vol. 5, No. 9, 01.09.2015, p. 773-783.

Research output: Contribution to journalArticle

Leatherman, BD, Khalid, A, Lee, S, Mcmains, K, Peltier, J, Platt, MP, Stachler, RJ, Toskala, E, Tropper, G, Venkatraman, G & Lin, SY 2015, 'Dosing of sublingual immunotherapy for allergic rhinitis: Evidence-based review with recommendations', International Forum of Allergy and Rhinology, vol. 5, no. 9, pp. 773-783. https://doi.org/10.1002/alr.21561
Leatherman, Bryan D. ; Khalid, Ayesha ; Lee, Stella ; Mcmains, Kevin ; Peltier, Jacques ; Platt, Michael P. ; Stachler, Robert J. ; Toskala, Elina ; Tropper, Guy ; Venkatraman, Giri ; Lin, Sandra Y. / Dosing of sublingual immunotherapy for allergic rhinitis : Evidence-based review with recommendations. In: International Forum of Allergy and Rhinology. 2015 ; Vol. 5, No. 9. pp. 773-783.
@article{54395f9713ce4d7eb3cbf5996f50c346,
title = "Dosing of sublingual immunotherapy for allergic rhinitis: Evidence-based review with recommendations",
abstract = "Background: Since the mid 1980s, the clinical use of sublingual immunotherapy (SLIT) has dramatically increased. However, 1 of the primary barriers to providing SLIT is lack of a published dosing recommendations. The purpose of this work is to provide a range of effective SLIT dosing based upon a rigorous review of the existing evidence base. An appendix with SLIT dosing recommendations is also included. Methods: A comprehensive search of the past 25 years of the medical literature using PubMed was performed for specific antigens. Inclusion criteria for articles included: randomized, placebo-controlled studies of SLIT, studies with clinical allergic rhinitis outcomes, and dosing units available to determine the micrograms per month of major allergen administered. The extracted data was used to compile a range of effective SLIT dosing for individual antigens. Results: Seventy-five articles met the inclusion criteria, providing a range of effective dosing for some allergens. There was commonly a wide range in doses for particular antigens between the individual studies. For some antigens, there was significant overlap in dosage amount between studies showing efficacy and lack of efficacy. Clinical trials meeting inclusion criteria are not available for many allergens. Conclusion: This study provided a comprehensive review of the published sublingual dosing ranges for specific antigens. The review provided a range of effective sublingual doses for some allergens, whereas for other allergens there was insufficient published data to determine specific doses. Recommendations for SLIT dosing were produced based on the data revealed in the review and expert opinion.",
keywords = "Aeroallergens, Allergic conjunctivitis, Allergy injections, Asthma, Evidence-based medicine, Subcutaneous immunotherapy, Sublingual immunotherapy, Type I allergy",
author = "Leatherman, {Bryan D.} and Ayesha Khalid and Stella Lee and Kevin Mcmains and Jacques Peltier and Platt, {Michael P.} and Stachler, {Robert J.} and Elina Toskala and Guy Tropper and Giri Venkatraman and Lin, {Sandra Y}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/alr.21561",
language = "English (US)",
volume = "5",
pages = "773--783",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Dosing of sublingual immunotherapy for allergic rhinitis

T2 - Evidence-based review with recommendations

AU - Leatherman, Bryan D.

AU - Khalid, Ayesha

AU - Lee, Stella

AU - Mcmains, Kevin

AU - Peltier, Jacques

AU - Platt, Michael P.

AU - Stachler, Robert J.

AU - Toskala, Elina

AU - Tropper, Guy

AU - Venkatraman, Giri

AU - Lin, Sandra Y

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: Since the mid 1980s, the clinical use of sublingual immunotherapy (SLIT) has dramatically increased. However, 1 of the primary barriers to providing SLIT is lack of a published dosing recommendations. The purpose of this work is to provide a range of effective SLIT dosing based upon a rigorous review of the existing evidence base. An appendix with SLIT dosing recommendations is also included. Methods: A comprehensive search of the past 25 years of the medical literature using PubMed was performed for specific antigens. Inclusion criteria for articles included: randomized, placebo-controlled studies of SLIT, studies with clinical allergic rhinitis outcomes, and dosing units available to determine the micrograms per month of major allergen administered. The extracted data was used to compile a range of effective SLIT dosing for individual antigens. Results: Seventy-five articles met the inclusion criteria, providing a range of effective dosing for some allergens. There was commonly a wide range in doses for particular antigens between the individual studies. For some antigens, there was significant overlap in dosage amount between studies showing efficacy and lack of efficacy. Clinical trials meeting inclusion criteria are not available for many allergens. Conclusion: This study provided a comprehensive review of the published sublingual dosing ranges for specific antigens. The review provided a range of effective sublingual doses for some allergens, whereas for other allergens there was insufficient published data to determine specific doses. Recommendations for SLIT dosing were produced based on the data revealed in the review and expert opinion.

AB - Background: Since the mid 1980s, the clinical use of sublingual immunotherapy (SLIT) has dramatically increased. However, 1 of the primary barriers to providing SLIT is lack of a published dosing recommendations. The purpose of this work is to provide a range of effective SLIT dosing based upon a rigorous review of the existing evidence base. An appendix with SLIT dosing recommendations is also included. Methods: A comprehensive search of the past 25 years of the medical literature using PubMed was performed for specific antigens. Inclusion criteria for articles included: randomized, placebo-controlled studies of SLIT, studies with clinical allergic rhinitis outcomes, and dosing units available to determine the micrograms per month of major allergen administered. The extracted data was used to compile a range of effective SLIT dosing for individual antigens. Results: Seventy-five articles met the inclusion criteria, providing a range of effective dosing for some allergens. There was commonly a wide range in doses for particular antigens between the individual studies. For some antigens, there was significant overlap in dosage amount between studies showing efficacy and lack of efficacy. Clinical trials meeting inclusion criteria are not available for many allergens. Conclusion: This study provided a comprehensive review of the published sublingual dosing ranges for specific antigens. The review provided a range of effective sublingual doses for some allergens, whereas for other allergens there was insufficient published data to determine specific doses. Recommendations for SLIT dosing were produced based on the data revealed in the review and expert opinion.

KW - Aeroallergens

KW - Allergic conjunctivitis

KW - Allergy injections

KW - Asthma

KW - Evidence-based medicine

KW - Subcutaneous immunotherapy

KW - Sublingual immunotherapy

KW - Type I allergy

UR - http://www.scopus.com/inward/record.url?scp=84940791661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940791661&partnerID=8YFLogxK

U2 - 10.1002/alr.21561

DO - 10.1002/alr.21561

M3 - Article

VL - 5

SP - 773

EP - 783

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 9

ER -